SLC5A2 and type 2 diabetes mellitus: The treatment of type 2 diabetes has been profoundly changed in the last years due to the possibility of prescribing the inhibitors of Na+-glucose cotransporter-2 (SGLT2i), which has a good effect on glycated hemoglobin reduction.